Kazuki Nozawa, Medical oncologist, shared on X:
“A new review on HER2DX and its evolving role in HER2-positive early breast cancer. ESMO Open. Truly honored to be part of this outstanding group of experts Sara Tolaney, G Curigliano, Nadia Harbeck, Javier Cortes and to contribute to this work.”
Title: HER2DX in early-stage HER2-positive breast cancer: a review of clinical utility
Authors: S.M. Tolaney, N. Tung, A.C. Wolff, A. DeMichele, J.M. Cejalvo, O. Martínez-Sáez, T. Pascual, A.G. Waks, K. Nozawa, H. Iwata, M. Martín, E. Ciruelos, N. Harbeck, L.A. Carey, J. Cortés, A. Llombart, P. Sharma, G. Curigliano.
Read the full article.
You can also read:
HERTHENA-Breast02 Trial: Innovative Dual-ADC Strategy in HR+/HER2-Low Breast Cancer
